Johann Morelle: Complement Inhibitors Are Reshaping Modern Nephrology
Johann Morelle, Professor of Nephrology, Head of the Division of Nephrology at University Hospitals Namur (CHU UCL Namur), shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Nephrology Dialysis Transplantation:
“Complement inhibitors are rapidly transforming the management of kidney diseases – from complement-mediated thrombotic microangiopathies (TMA/aHUS) to glomerular diseases such as C3 glomerulopathy (C3G), primary immunoglobulin-associated MPGN (Ig-MPGN) and IgA nephropathy (IgAN).
In our new review published in Nephrology Dialysis Transplantation (NDT), the journal of the European Renal Association (ERA), we discuss the mechanistic basis of infection risk under complement inhibition (eculizumab, ravulizumab, iptacopan, pegcetacoplan) and propose a pragmatic framework for infection-risk mitigation in nephrology practice.
Key take-home messages:
- Infection risk under complement inhibition is target-dependent
- Prevention strategies should integrate vaccination, antimicrobial prophylaxis, patient education, and rapid-access pathways for febrile illness
- CKD, dialysis, transplantation, and concomitant immunosuppression further modulate infectious vulnerability.
Grateful to Mathilde Berghmans, Francois Seghers, Safak Mirioglu, and Andreas Kronbichler for the outstanding collaboration!”
Title: Infection risk mitigation with complement inhibitors in kidney disease
Authors: Mathilde Berghmans, François Seghers, Safak Mirioglu, Andreas Kronbichler, Johann Morelle
Stay updated on all scientific advances with Hemostasis Today.
-
May 30, 2026, 10:17Factor X Deficiency – From Mild Bruising to Life Threatening Hemorrhage – ICHCC
-
May 30, 2026, 09:49Flora Peyvandi: Exploring a Multidisciplinary Care Model for Hemophilia and Rare Diseases
-
May 30, 2026, 08:59Li-Chia Chen: Advancing Patient Care Through Pharmacist Innovation at KUTRRH
-
May 30, 2026, 08:58Ben Creagh-Brown: How Should HI-PEITHO Influence the Management of Intermediate-Risk Pulmonary Embolism?
-
May 30, 2026, 08:56Reidiel Suárez Borges: Understanding the INR in Anticoagulation Management
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center
-
May 29, 2026, 17:20Martin Widschwendter: How Molecular Detection Tests Could Transform Endometrial Cancer Care
-
May 29, 2026, 17:18Nina Lansbury: Supporting a Period Friendly World With Menstrual Health Research and Education